The University of Rochester Medical Center’s (UR Medicine) Lupus Clinic is preparing for its ninth annual Lupus Education Day, which is running on Saturday, October 31, 2015, at 3:30 p.m. at the Helen Wood Hall, 255 Crittenden Blvd. Local patients, their loved ones, and caregivers are all invited to this free event to know more about the latest findings and developments in the field of lupus research and management.
“This educational and networking opportunity is one that our patients look forward to every year,” said Jennifer Anolik, MD, PhD, director of UR Medicine’s Lupus Clinic, known throughout the country for being at the forefront of clinical disease management and research. Dr. Anolik also works closely with Dr. R. John Looney, a rheumatologist, allergist and clinical immunologist.
Attendees can expect to learn about the latest updates in lupus research; patient care; ongoing and upcoming clinical studies; nutrition’s role in disease management, coping, and wellness; how best to prevent the disease; and how to spot the early signs and symptoms in order to begin timely treatment. The program will also feature an open panel discussion.
Those interested to attend UR Medicine’s Lupus Education Day can contact Joy Gangross through (585) 275-2891 to register. To know more about UR Medicine’s Lupus Clinic, visit http://www.urmc.rochester.edu/medicine/allergy/patients-families/lupus-clinic.cfm.
Systemic lupus erythematosus is a disease in which the body’s own immune system attacks several organs, with the kidney accounting for the most affected organ. Lupus is about nine times more common in women than in men. Unfortunately, the disease currently has no cure, although therapies and diagnosis can improve symptoms and survival. The disease can flare-up unexpectedly, leading to frequent costly medical problems. Biomarkers that might predict flare-ups would be potentially helpful for preventative treatments.
In the largest case–control study of lupus DAH reported to date entitled “Systemic lupus erythematosus complicated by diffuse alveolar haemorrhage: risk factors, therapy and survival”, a team of researchers from the Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor in Michigan led by Dr. Jason S Knight, examined 22 cases of DAH in a SLE cohort of nearly 1000 patients, and compared them to 66 controls from the same outpatient cohort.
SHOULD THIS BE DELETED?? (grace)